A novel, label‐free, pre‐equilibrium assay to determine the association and dissociation rate constants of therapeutic antibodies on living cells

Abstract

AbstractBackground and PurposeMonoclonal antibodies (Ab) represent the fastest growing drug class. Knowledge of the biophysical parameters (kon, koff and KD) that dictate Ab:receptor interaction is critical during the drug discovery process. However, with the increasing complexity of Ab formats and their targets, it became apparent that existing technologies present limitations and are not always suitable to determine these parameters. Therefore, novel affinity determination methods represent an unmet assay need.Experimental ApproachWe developed a pre‐equilibrium kinetic exclusion assay using recent mathematical advances to determine the kon, koff and KD of monoclonal Ab:receptor interactions on living cells. The assay is amenable to all human IgG1 and rabbit Abs.Key ResultsUsing our novel assay, we demonstrated for several monoclonal Ab:receptor pairs that the calculated kinetic rate constants were comparable with orthogonal methods that were lower throughput or more resource consuming. We ran simulations to predict the critical conditions to improve the performance of the assays. We further showed that this method could successfully be applied to both suspension and adherent cells. Finally, we demonstrated that kon and koff, but not KD, correlate with in vitro potency for a panel of monoclonal Abs.Conclusions and ImplicationsOur novel assay has the potential to systematically probe binding kinetics of monoclonal Abs to cells and can be incorporated in a screening cascade to identify new therapeutic candidates. Wide‐spread adoption of pre‐equilibrium assays using physiologically relevant systems will lead to a more holistic understanding of how Ab binding kinetics influence their potency.